AstraZeneca and Ionis have suffered a major late-stage setback after Wainua/Wainzua (eplontersen) failed to hit the primary endpoint in a phase 3 trial in transthyretin-mediated amyloid cardiomyopathy ...

Denmark's Genmab said adding its bispecific antibody petosemtamab to MSD's Keytruda (pembrolizumab) cut the risk of death by ...

Swiss DARPin specialist Molecular Partners is shifting its entire focus to radiopharmaceuticals and plans to cut up to 55 ...

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...

From Berlin biotech NOXXON through a strategic realignment and considerations of cryptocurrency investments, and now back to ...

Spanish biotech ALLOX has closed a €9.4 million ($10.5 million) seed round, led by Asabys with participation from Spanish and ...

Beyond the main headlines, European biotech kept moving this week. This edition of Meanwhile in Biotech covers an Alzheimer’s ...

Swiss pharma group Ferring Pharmaceuticals has agreed to acquire New York-based Gameto for up to $1.3825 billion (€1.24 ...

Switzerland-based Idorsia has launched a new pivotal Phase 3 trial of lucerastat in Fabry disease, targeting kidney deposits ...

Congress is one of the biggest events on the cancer research calendar, where clinical results can reshape treatment decisions ...

Portugal-based Exogenus Therapeutics will lead a five-year, €13 million Horizon Europe project to advance its osteoarthritis ...

Merck KGaA is acquiring British biotech company Silence Therapeutics for $1.3 billion. The main value driver is an siRNA ...